The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of &bgr；-catenin. The disclosure also relates to applications in the treatment of scleroderma, including diffuse systemic sclerosis and limited systemic sclerosis, and pharmaceutical compositions comprising such alpha helix mimetic &bgr；-catenin inhibitors.
